Intuitive Surgical: The Market Is Pricing in a Nightmare the Numbers Don't Support

Intuitive Surgical's shares languish near a 52-week low despite a 19% revenue surge and earnings beat, as FDA clearance of J&J's Ottava robot and a U.S. procedure slowdown spook investors.

A 19% revenue surge, earnings that crushed expectations by nearly 12%, and a stock trading within spitting distance of its 52-week low. That disconnect — between what Intuitive Surgical is delivering operationally and what investors are paying for it — has rarely been this stark. The shares have shed 38.7% since January, closing Friday at €296.35 after a modest 1.58% bounce. That's just 2.5% above the 52-week trough of €289.05 hit on July 23, and nearly 43% below the January record of €516.50.

The proximate cause of the sell-off arrived on July 22, when the FDA granted Johnson & Johnson de-novo clearance for its Ottava surgical robot. Unlike Intuitive's da Vinci systems, Ottava integrates its robotic arms directly into the operating table — a space-saving design that J&J hopes will appeal to crowded ORs. For now, the clearance covers only soft-tissue procedures such as appendectomies, but the symbolism is unmistakable: after years of watching rivals fail to dent its dominance, Intuitive Surgical faces its most credible U.S. challenger yet.

J.P. Morgan analysts argue that Intuitive's deep entrenchment in hospital workflows — training programs, instrument contracts, service agreements — will preserve its leadership. The market, however, chose to focus on the end of a quasi-monopoly rather than the durability of a moat. Headlines trumpeted the arrival of a competitor, and the stock took the hit.

Yet the Ottava threat remains largely theoretical for now. J&J plans a controlled, selective rollout. Meanwhile, Intuitive's installed base continues to expand, and the switching costs embedded in each new da Vinci installation are formidable. A hospital that buys a da Vinci 5 today locks its operating room budget — and its surgeon training pipeline — to Intuitive for the better part of a decade. Competitors don't undo that kind of lock-in overnight.

The second-quarter numbers, released alongside the Ottava news, should have provided ballast. Revenue hit $2.89 billion, up 18.5% year-over-year and comfortably ahead of the $2.82 billion consensus. Adjusted earnings per share of $2.80 blew past the $2.51 forecast. Global procedure volume grew 16%. Beneath the headline strength, though, a deceleration in the U.S. market caught the market's attention: domestic procedure growth slowed to 12%, the weakest pace since 2021.

Management attributed the U.S. slowdown to the expiration of enhanced ACA subsidies, which has prompted some patients to postpone elective procedures such as hernia repairs and gallbladder removals. The same dynamic, combined with the impact of GLP-1 weight-loss drugs on bariatric surgery volumes, is creating near-term headwinds that the company says are temporary. It held firm on its full-year 2026 procedure growth guidance of 13.5% to 15.5%.

Some analysts read that unchanged guidance — delivered alongside a major earnings beat — as a cautious signal. Others see it as prudent conservatism in the face of transient pressures. Either way, the market has chosen to price in the worst-case scenario.

The da Vinci 5 platform remains the structural story that the sell-off has obscured. In the second quarter, 246 of the 468 new systems installed were da Vinci 5 units — 52.6% of the total. That adoption rate signals a generational platform shift, not a product cycle losing steam. And because roughly 85% of Intuitive's revenue comes from recurring sources — instruments, accessories, and service contracts tied to each procedure — the installed base acts as a revenue flywheel that competitor inroads cannot quickly disrupt.

Technically, the stock is flashing oversold signals. The 14-day relative strength index stands at 31.9, just above the 30 threshold that often precedes a bounce. The annualized 30-day volatility of 54.6% reflects the whipsaw of recent weeks, but the analyst consensus price target of €431.15 implies 43.8% upside from current levels.

Institutional positioning tells a mixed story. Renaissance Technologies trimmed its stake. Lazard Asset Management added to its position. That tug-of-war mirrors the broader debate: is this a structural breakdown or a sentiment-driven overreaction?

The answer likely depends on whether the U.S. procedure slowdown proves transitory and whether Ottava gains real traction. Neither question will be settled in a single quarter. But for a company trading at a 43% discount to its January peak while generating accelerating revenue and expanding its next-generation platform, the market appears to be pricing in a crisis the numbers do not yet support.